Article

Structural and functional analysis of VYD222: a broadly neutralizing antibody against SARS-CoV-2 variants

2025-08-28

Abstract excerpt

Extensive mutations in SARS-CoV-2 spike protein have rendered most therapeutic monoclonal antibodies (mAbs) ineffective. However, here we describe VYD222 (pemivibart), a human mAb re-engineered from ADG20 (adintrevimab), which maintains potency despite substantial virus evolution. VYD222 received FDA Emergency Use Authorization for pre-exposure prophylaxis of COVID-19 in certain immunocompromised adults and adoles...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7d91fbae-ca5a-5be4-b83e-f9d4cdd292d6
DOI: 10.1101/2025.08.28.672883

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Structural and functional analysis of VYD222: a broadly neutralizing antibody against SARS-CoV-2 variantsDOI 10.1101/2025.08.28.672883Read

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibodySemantic proximity Read

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognitionSemantic proximity Read

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsSemantic proximity Read

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognitionSemantic proximity Read

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read

Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational lockingSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

A broad and potent neutralization epitope in SARS-related coronavirusesSemantic proximity Read

Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibodySemantic proximity Read

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usageSemantic proximity Read